LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial

Petrie, John; Marso, Steven; Bain, Stephen; Franek, Edward; Jacob, Stephan; Masmiquel, Luis; Leiter, Lawrence; Haluzik, Martin; Satman, İlhan; Omar, Mohamed; Shestakova, Marina; Van Gaal, Luc; Mann, Johannes; Baeres, Florian; Zinman, Bernard; Poulter, Neil

doi:10.1097/hjh.0000000000000890

LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial

Petrie J. R., Marso S. P., Bain S. C., Franek E., Jacob S., Masmiquel L., ...More

JOURNAL OF HYPERTENSION, vol.34, no.6, pp.1140-1150, 2016 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 34 Issue: 6
Publication Date: 2016
Doi Number: 10.1097/hjh.0000000000000890
Journal Name: JOURNAL OF HYPERTENSION
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1140-1150
Keywords: blood pressure, cardiovascular disease, glucagon-like peptide-1, regional differences, targets, type 2 diabetes mellitus, EUROPEAN-SOCIETY, HYPERTENSION MANAGEMENT, OUTCOMES, LIRAGLUTIDE, COMBINATION, PREVENTION, GUIDELINES, METFORMIN, WEIGHT, SAFETY
Istanbul University Affiliated: Yes

Abstract

Objective: As glucagon-like peptide-1 receptor agonists lower blood pressure (BP) in type 2 diabetes mellitus (T2DM), we examined BP control in relation to targets set by international bodies prior to randomization in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial.